Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies

Next Previous
Trial Profile

A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CM 24 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer
  • Focus Adverse reactions; First in man
  • Sponsors cCAM Biotherapeutics; Merck Sharp & Dohme

    • Most Recent Events

    • 31 May 2020 Results (n=27) presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
    • 14 May 2020 Results published in the Kitov Pharmaceuticals Media Release.
    • 14 May 2020 According to an Kitov Pharmaceuticals media release, data from this study will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top